GoodRx Q1 revenue $184M beats guidance; adjusted EBITDA $53.2M

GoodRx Holdings, Inc.

2023-Q1 EPS reported -$0.01 revenue$183,986,000

Revenue $184.0M exceeds guidance; adjusted EBITDA $53.2M (28.9% margin) also above range.
Net loss $3.3M includes $25.5M stock-based comp; adjusted net income $29.5M (16.0% margin).
Scott Wagner appointed Interim CEO; Trevor Bezdek remains Chairman; leadership aims to accelerate growth.
Over 450,000 prescribers engaged via Provider Mode; over 7M consumers of prescription offerings.
Operating cash flow $32.3M in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

GoodRx Holdings, Inc. reported the three months ended March 31, 2023 results: revenue $184.0 million, net income $3.3 million.

Period: the three months ended March 31, 2023
Revenue: $184.0 million
Net income: $3.3 million
Result: reported results

Exact text from the filing

or the “Company”) , a leading digital healthcare platform, has released its financial results for the first quarter 2023. First Quarter 2023 Highlights • Total revenue of $184.0 million, exceeding previously announced guidance • Net loss of $3.3 million 1 ; Net loss margin of 1.8% • Adjusted Net Income 2 of $29.5 million; Adjusted Net Income Margin 2 of 16.0% •

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.